Effects of deferiprone on immune status and cytokine pattern in thalassaemia major

被引：39

作者：

Del Vecchio, GC ^{[1
]}

Schettini, F ^{[1
]}

Piacente, L ^{[1
]}

De Santis, A ^{[1
]}

Giordano, P ^{[1
]}

De Mattia, D ^{[1
]}

机构：

[1] Univ Bari, Policlin, Dipartimento Biomed Eta Evolut, I-70124 Bari, Italy

来源：

ACTA HAEMATOLOGICA | 2002年 / 108卷 / 03期

关键词：

cytokine; deferiprone (L1); immunity; thalassaemia;

D O I：

10.1159/000064705

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Objective: The present study was undertaken to evaluate the possible occurrence of immunological abnormalities in thalassaemia major patients treated with deferiprone (L1). Methods: Longitudinal observational cohort study. Results: The absolute number of CD8+ lymphocytes was high and the CD4/CD8 ratio low before L1 treatment; these parameters returned to normal after 3 months of L1 treatment. TNF-alpha, IL-2 and IL-2sRalpha were elevated before L1 treatment (11.83 +/- 1.75, 11.75 +/- 3.91, 1,409 +/- 621 pg/ml, respectively), while IL-6 was normal (2.58 +/- 0.79 pg/ml). After 12 months of treatment, IL-10 was higher than in previous periods, although always within the normal range. TNF-alpha, IL-2 and IL-2sRalpha returned to normal after 12, 6, and 3 months of L1 treatment, respectively. Copyright (C) 2002 S. Karger AG, Basel.

引用

页码：144 / 149

页数：6

共 32 条

[1]

ANTIN JH, 1992, BLOOD, V80, P2964

[2]

Bartfay WALLY J., 1999, Hematology, V4, P67

[3]

Reduction of tumour necrosis factor α expression and signalling in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine [J].